Evommune, Inc. (EVMN)
NYSE:EVMN
Want to see EVMN full AI Analyst Report?
EVMN Stock Chart & Stats
$27.45
--
Market closed
$27.45
--
Day’s Range― - ―
52-Week Range$13.89 - $33.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)935.27K
Market Cap
$713.88M
Enterprise Value$289.83M
Total Cash (Recent Filing)$211.46M
Total Debt (Recent Filing)$9.11M
Price to Earnings (P/E)―
Beta0.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue28.98
Enterprise Value/Gross Profit31.25
Enterprise Value/Ebitda-3.66
Forecast
1Y Price Target
$52.00Price Target Upside89.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetA major recapitalization flipped equity to $205.6M and cut debt nearly to zero, materially reducing leverage and solvency risk. This durable balance-sheet repair provides financing optionality to fund mid-stage development, support partnerships, and absorb execution variance over the coming years.
Clinical Validation (EVO301 Phase 2a)EVO301’s Phase 2a met efficacy endpoints with a clean safety profile and biomarker reductions, validating IL‑18 inhibition. This durable mechanistic proof increases the probability of progression, supports indication expansion and partnering discussions, and strengthens long-term commercial prospects beyond a single trial.
Diversified Mid-stage PipelineAn oral MRGPRX2 antagonist pursuing CSU, AD and planned migraine studies creates multiple development paths and market entry points. This multi-indication strategy spreads clinical risk, enlarges addressable markets and yields several durable catalysts across 2026–2027 to support long-term value creation.
Bears Say
Accelerating Cash BurnOperating and free cash flow have deteriorated materially, reflecting rising R&D and operating spend. The accelerating cash burn implies ongoing financing need unless costs drop or revenues scale, creating dilution and execution risk that can pressure strategic flexibility over the medium term.
Persistent Large Net LossesDespite revenue growth, the company remains deeply loss-making with losses widening in absolute terms. The structural gap between current revenues and operating cost base delays a credible path to profitability and stresses margins, constraining long-term financial resilience absent clinical or commercial success.
Binary Clinical DependenceNear-term corporate trajectory depends on pivotal mid-stage EVO756 readouts; unfavorable outcomes would materially impair commercial prospects, partnership interest and funding visibility. This binary clinical risk is a structural vulnerability for the next 2–6 months and affects strategic optionality.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $13.88 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $713.88M.
When is Evommune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evommune, Inc.’s earnings last quarter?
Currently, no data Available
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 36,018,370 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.00 (89.44% Upside)
$52.00 (89.44% Upside)
Blogger Sentiment
Bullish
EVMN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-195.15%
Trailing 12-Months
Asset Growth
475.65%
Trailing 12-Months
Company Description
Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$52.00
▲(89.44% Upside)
Ownership Overview
52.56% Insiders
10.70% Mutual Funds
10.56% Other Institutional Investors
23.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---